Table III

Comparison of two reports for ovarian cancer diagnosis based on SELDI-TOF technology

StudyChip typeDistinguishing peaks, m/zaDiagnostic sensitivity and specificityb
Petricoin et al. (30)C-16534, 989, 2,111, 2,251, 2,465100%; 95%
Kozak et al. (44)SAX2cScreening biomarker paneld:96%; 83%
4,400, 15,900, 18,900, 23,000, 30,100
Validation biomarker panel 1e:82%; 95%
3,100, 13,900, 21,000, 79,000, 106,700
Validation biomarker panel 2f:73%; 95%
5,100, 16,900, 28,000, 93,000
  • a m/z ratios were rounded to whole numbers for simplicity.

  • b Somewhat different values were obtained for different sets of samples; see original papers for more details.

  • c Strong anion-exchange chip.

  • d Differentiates healthy from neoplastic (benign and malignant) disease. In this paper, the molecular masses of the markers are given instead of m/z ratios. All values were reported with one decimal point accuracy.

  • e Differentiates healthy and benign disease from malignant disease.

  • f In Ref. 30, there is a limit to the molecular mass or m/z ratio monitored (up to 20,000).